Figure 2 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer

Read full text
Authors: Alessia Centonze, Adrià-Jaume Roura, Meritxell Novillo-Font, Cristina Giordano, Xavier Hernando‐Momblona, Montserrat Llanses, Paula Prats, Marta Sevillano, Débora Cabot, Mireia Novell, Gabriel Pabst, Florian Andersch
+19 more Adrià Cañellas-Socias, Chong Zhang, Nikolaos-Nikiforos Giakoumakis, Hugh Sparks, Christopher W. Dunsby, Julien Colombelli, Asunción Fernández‐Barral, Elena Sancho, Camille Stephan‐Otto Attolini, Alberto Múñoz, Antonio Barbáchano, Héctor G. Pálmer, Jordi Martínez‐Quintanilla, Johannes A. Zuber, Cristina Blaj, Elsa Quintana, Carme Cortina, Marc A. Martı́-Renom, Eduard Batlle
Cited by: 0

Abstract

Plasticity between Lgr5+ CSC to Emp1+ HRC states by KRAS activity across models. A, Growth (CellTiter-Glo) of AKTP MTOs treated with vehicle or RMC-9945 for 9 days normalized to day 0 of treatment. Mean ± SEM. P values between vehicle day 2 and RMC-9945 day 4, 6, or 9 are derived from ANOVA followed by Šídák multiple comparisons test. B, Gene set enrichment analysis of AKTP MTOs upon vehicle versus RMC-9945 treatment. C, Relative mRNA expression of indicated marker genes in vehicle-treated and RMC-9945–treated AKTP MTOs for 48 hours assessed by RT-qPCR. Mean ± SEM. P values are derived from ANOVA followed by Šídák multiple comparisons test. D, CRISPR-Cas9 targeting strategy to introduce APK mutations in normal mucosa (NM) organoids derived from C57BL/6J mice. E and F, Boxplots depicting the normalized and z-scored expression of Lgr5+ ISC gene signature (E) and EpiHR signature (F) in APK CTOs treated with either vehicle or RMC-9945 for 48 hours. t test was used to assess median differences. G, Gene set enrichment analysis (GSEA) of APK CTOs upon vehicle and RMC-9945 treatment. H, Growth (CellTiter-Glo) of PDO131 treated with vehicle or RMC-9945 for 10 days normalized to day 0 of treatment. I, Differential gene expression analysis of CSC and HRC key genes for PDO 131. J, GSEA of PDO131 in vehicle versus RMC-9945 treatment. K, Growth (CellTiter-Glo) of PDO C31M treated with vehicle or RMC-9945 for 10 days normalized to day 0 of treatment. L, Differential gene expression analysis of CSC and HRC key genes for PDO C31M. M, GSEA of PDO C31M in vehicle versus RMC-9945 treatment. PDOs were treated with RMC-9945 for 4 days and subjected to RNA-seq analysis. Dusp6 gene is included as a reference for KRAS/MAPK pathway inhibition. Log2 fold change (FC) and adjusted P value are shown. For GSEA, selected Hallmark, GOCC, Kyoto Encyclopedia of Genes and Genomes, and custom gene signatures are shown. NES, normalized enrichment score. P value < 0.05 for all gene sets, color gradient represents significance as shown. For the growth curves, P values are derived from multiple unpaired t test.

Fields of Study & Subjects

Cancer Cells and Metastasis Colorectal Cancer Treatments and Studies Cancer Genomics and Diagnostics

Publication details

Publication date
6 February 2026